Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-highest quintile among peers.
BlackRock Health Sciences Opps Inv A SHSAX
- NAV / 1-Day Return 67.93 / −0.32 %
- Total Assets 8.2 Bil
-
Adj. Expense Ratio
- Expense Ratio 1.090%
- Distribution Fee Level Low
- Share Class Type Front Load
- Category Health
- Investment Style Large Blend
- Min. Initial Investment 1,000
- Status Open
- TTM Yield 0.23%
- Turnover 29%
USD | NAV as of Apr 25, 2024 | 1-Day Return as of Apr 25, 2024, 10:14 PM GMT+0
Morningstar’s Analysis SHSAX
Will SHSAX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 48.7
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 9.93 | 855.6 Mil | Healthcare |
UnitedHealth Group Inc | 8.20 | 706.9 Mil | Healthcare |
AbbVie Inc | 5.42 | 466.9 Mil | Healthcare |
Boston Scientific Corp | 4.86 | 419.2 Mil | Healthcare |
Merck & Co Inc | 4.62 | 398.3 Mil | Healthcare |
Amgen Inc | 3.47 | 298.8 Mil | Healthcare |
Abbott Laboratories | 3.45 | 297.0 Mil | Healthcare |
Danaher Corp | 3.15 | 271.4 Mil | Healthcare |
Intuitive Surgical Inc | 2.81 | 242.4 Mil | Healthcare |
Stryker Corp | 2.81 | 242.1 Mil | Healthcare |